Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › SRPT

Sarepta Therapeutics

SRPT Rare disease Lead: Approved 10 Biotech Distilled articles ↓ 29 filings & releases ↓ Cash $473M (Sep 30, 2026) ↓ 10 verdicts ↓ 2 timing quotes ↓
NeurologyRespiratory Gene TherapyNucleic Acid

Market cap $1.91B 107.2M shares (10-Q, Nov 2, 2026) × $17.82 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Catalent clean room agreement corporate4Q 2026Catalent clean room agreement corporate, 4Q 2026, routine
  2. ELEVIDYS readout1Q 2027ELEVIDYS readout, 1Q 2027, major
  3. ELEVIDYS ENDEAVOR readout1Q 2027ELEVIDYS ENDEAVOR readout, 1Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (11 active programs)

Technology platforms

AAVrh74

Adeno-associated virus vector platform using the AAVrh.74 serotype to deliver gene therapy transgenes to target muscle cells; used for Duchenne muscular dystrophy (ELEVIDYS/SRP-9001) and limb-girdle muscular dystrophy programs (SRP-9003). Platform technology designation previously granted by FDA in June 2025, subsequently revoked.

Targets: dystrophin, beta-sarcoglycan

αvβ6 integrin-targeted delivery platform

siRNA delivery platform utilizing αvβ6 integrin targeting for muscle diseases, including facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1)

Targets: αvβ6 integrin

Discontinued (3)

Capital (as filed)

Cash
$473M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$406M Sep 30, 2026
Long-term investments
$109M Sep 30, 2026
Operating cash flow
$60.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$999M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Sarepta Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-02-13 Speculative buy speculative Sarepta Therapeutics (SRPT): Scientific Deep Dive for Lead and Pipeline Products Three-year ELEVIDYS efficacy data provides durable disease-modification receipts, revenue ramp is undeniable, and sirolimus-based Cohort 8 is a scientifically sound mitigation for AAV toxicity risk.
  2. 2026-03-01 Hold UPDATE: Sarepta (SRPT) - The Captain Bails Before the Storm? Abrupt CEO departure introduces acute execution risk; hold existing position but keep powder dry until 1,200-patient safety data at MDA Congress in March clarifies the AAV toxicity profile.
  3. 2026-03-08 Hold UPDATE: Sarepta Therapeutics (SRPT) - The Other Shoe Drops 10-K reveals $165M AAV manufacturing write-offs and $884M Arrowhead charge confirming operational and financial risks; maintain hold while watching Q1 siRNA data and MDA Congress safety presentation.
  4. 2026-03-21 Hold UPDATE: Sarepta Therapeutics (SRPT) - Fortifying the Shield and Unsheathing the Sword PMO full-approval submissions de-risk the cash-flowing Shield while Cohort 8 enrollment begins the most important binary catalyst; maintain position but wait to add until Q3/Q4 Cohort 8 liver toxicity data.
  5. 2026-03-28 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - Unsheathing the Sword First clinical siRNA data validates the $883M Arrowhead investment by demonstrating muscle delivery without dose-limiting toxicity, de-risking the thesis and making the $19.97 level an attractive entry ahead of the Huntington's INSIGHTT dosing catalyst.
  6. 2026-04-27 Hold UPDATE: Sarepta Therapeutics (SRPT) - The 10-K Mea Culpa Three of four original BUY assumptions broke (ESSENCE failed, AAVrh74 platform designation revoked, LGMD on clinical hold, EMA refused ELEVIDYS); the free pipeline option is gone and the thesis is now a binary-event hold on Cohort 8.
  7. 2026-05-06 Hold UPDATE: Sarepta Therapeutics (SRPT) - The Headline Beat That Wasn't Q1 ELEVIDYS product revenue collapsed 73% YoY to $102M; the headline GAAP profit is an accounting artifact from a Roche option decline; the thesis is now a single-event hold on Cohort 8 sirolimus data in late Q4 2026/Q1 2027.
  8. 2026-06-30 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The FDA Took the Meeting FDA accepting the PMO sNDAs for review modestly de-risks the Shield from FDORA withdrawal threat, but the dominant variable remains Cohort 8 sirolimus data; at $17.97 the stock is closer to fair value for a binary-hold than at prior levels.
  9. 2026-07-28 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The Chair Gets Filled Naming a credible development-and-regulatory CEO (ex-AbbVie R&D chief Severino) retires the leadership-vacuum risk premium, but the Cohort 8 binary and deteriorating product run-rate are unchanged; at $15.89 the stock is priced as a genuine binary-hold.
  10. 2026-08-06 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The Clock Slips a Quarter Q2 cash build and stable revenue floor are positives, but Cohort 8 full enrollment slipped to year-end 2026 with 12-week data now in Q1 2027, extending the binary hold by a quarter with no intervening catalysts larger than Phase 1/2 MAD siRNA data.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)